INDIANAPOLIS, May 28, 2026
Eli Lilly and Company has announced a major slate of scientific presentations for the American Diabetes Association (ADA) 86th Scientific Sessions, highlighting new clinical data for Foundayo (orforglipron), Mounjaro (tirzepatide), and retatrutide. The presentations underscore Lilly’s expanding leadership in obesity, type 2 diabetes, and cardiometabolic disease, showcasing innovative therapies designed to offer greater treatment choice and improved outcomes for millions of patients worldwide. The company’s data package includes pivotal Phase 3 results, new subgroup analyses, and quality-of-life findings that could help shape the future of obesity and diabetes management. As global rates of obesity and diabetes continue to rise, Lilly’s growing portfolio is positioned to address significant unmet medical needs across multiple cardiometabolic conditions.
Retatrutide Delivers Strong Phase 3 Results in Obesity and Diabetes
One of the most anticipated highlights at ADA 2026 is the presentation of Phase 3 data for retatrutide, Lilly’s investigational triple receptor agonist targeting GIP, GLP-1, and glucagon receptors. Results from the TRIUMPH-1 study demonstrated remarkable weight-loss efficacy, with adults living with obesity achieving an average weight reduction of up to 70.3 pounds (28.3%) over 80 weeks. In the TRANSCEND-T2D-1 trial, retatrutide delivered substantial metabolic improvements in adults with type 2 diabetes, reducing HbA1c by up to 2.0% while producing an average weight loss of 36.6 pounds (16.8%) within 40 weeks.
These findings further strengthen the growing evidence supporting retatrutide as a potential next-generation therapy capable of addressing obesity, diabetes, and related metabolic complications through a multi-target mechanism. Lilly is currently evaluating retatrutide in a broad Phase 3 development program spanning cardiovascular disease, sleep apnea, liver disease, osteoarthritis, and chronic pain indications.
Foundayo Strengthens Position in Oral GLP-1 Therapy
Advertisement
Lilly will also present pivotal findings from the ACHIEVE Phase 3 program evaluating Foundayo (orforglipron), the only approved oral GLP-1 receptor agonist that can be taken without food or water restrictions. In the ACHIEVE-2 trial, Foundayo reduced HbA1c by up to 1.7%, outperforming dapagliflozin. The ACHIEVE-3 study demonstrated superiority over oral semaglutide, delivering greater blood glucose control and 73.6% greater relative weight loss after 52 weeks of treatment. Meanwhile, the ACHIEVE-5 trial showed HbA1c reductions of up to 2.1% when used alongside insulin glargine.
Additional analyses from the ATTAIN program revealed significant weight loss benefits across all stages of menopause, including weight reductions exceeding 14% in peri-menopausal and post-menopausal women, highlighting Foundayo’s potential role in addressing diverse patient populations. The findings reinforce Lilly’s ambition to redefine the oral incretin therapy market through convenient, effective, and patient-friendly treatment options.
Mounjaro Continues to Demonstrate Long-Term Patient Benefits
New data for Mounjaro (tirzepatide) further expand the evidence supporting its role in type 2 diabetes management. Results from the SURPASS-CVOT and SURPASS-EARLY analyses demonstrated meaningful improvements in quality of life, daily functioning, physical health, and psychosocial well-being among adults receiving long-term treatment. These findings complement Mounjaro’s established efficacy in glycemic control and weight management while emphasizing outcomes that matter directly to patients.
Collectively, the ADA 2026 presentations highlight Lilly’s comprehensive cardiometabolic strategy, combining approved medicines with late-stage investigational therapies to create a broad portfolio capable of serving patients across the continuum of obesity and diabetes care. With multiple Phase 3 successes and expanding clinical evidence, Lilly continues to strengthen its position as one of the leading innovators driving the next generation of metabolic disease treatment.
Source: Eli Lilly press release
